Veracyte, Inc. (VCYT): Price and Financial Metrics


Veracyte, Inc. (VCYT): $20.58

-1.33 (-6.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VCYT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VCYT POWR Grades

  • Growth is the dimension where VCYT ranks best; there it ranks ahead of 86.04% of US stocks.
  • VCYT's strongest trending metric is Stability; it's been moving up over the last 177 days.
  • VCYT's current lowest rank is in the Momentum metric (where it is better than 1.17% of US stocks).

VCYT Stock Summary

  • Price to trailing twelve month operating cash flow for VCYT is currently 210.37, higher than 98.37% of US stocks with positive operating cash flow.
  • The ratio of debt to operating expenses for VERACYTE INC is higher than it is for about just 11.75% of US stocks.
  • VCYT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 7.65% of US stocks.
  • Stocks that are quantitatively similar to VCYT, based on their financial statements, market capitalization, and price volatility, are HBIO, LPTH, MNDY, STAA, and ICHR.
  • Visit VCYT's SEC page to see the company's official filings. To visit the company's web site, go to www.veracyte.com.

VCYT Valuation Summary

  • In comparison to the median Healthcare stock, VCYT's price/sales ratio is 12.77% higher, now standing at 5.3.
  • Over the past 114 months, VCYT's EV/EBIT ratio has gone down 25.8.

Below are key valuation metrics over time for VCYT.

Stock Date P/S P/B P/E EV/EBIT
VCYT 2023-03-24 5.3 1.5 -43.4 -39.7
VCYT 2023-03-23 5.4 1.5 -43.7 -40.0
VCYT 2023-03-22 5.3 1.5 -43.1 -39.4
VCYT 2023-03-21 5.7 1.6 -45.9 -42.2
VCYT 2023-03-20 5.5 1.5 -44.4 -40.7
VCYT 2023-03-17 5.5 1.5 -44.3 -40.6

VCYT Growth Metrics

    The 2 year revenue growth rate now stands at 105.47%.
  • Its 4 year price growth rate is now at 247.13%.
  • The year over year net cashflow from operations growth rate now stands at 100.15%.
VCYT's revenue has moved up $163,207,000 over the prior 33 months.

The table below shows VCYT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 283.575 6.237 -43.244
2022-06-30 268.353 -2.182 -48.65
2022-03-31 250.594 0.068 -48.156
2021-12-31 219.514 -31.621 -75.563
2021-09-30 186.714 -37.806 -73.079
2021-06-30 157.465 -34.661 -63.074

VCYT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VCYT has a Quality Grade of D, ranking ahead of 19.15% of graded US stocks.
  • VCYT's asset turnover comes in at 0.213 -- ranking 68th of 81 Healthcare stocks.
  • CHE, HCSG, and NTRA are the stocks whose asset turnover ratios are most correlated with VCYT.

The table below shows VCYT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.213 0.673 -1.427
2021-03-31 0.224 0.662 -1.543
2020-12-31 0.327 0.647 -0.827
2020-09-30 0.360 0.642 -0.795
2020-06-30 0.425 0.652 -0.693
2020-03-31 0.462 0.670 -0.490

VCYT Price Target

For more insight on analysts targets of VCYT, see our VCYT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $63.17 Average Broker Recommendation 1.5 (Moderate Buy)

VCYT Stock Price Chart Interactive Chart >

Price chart for VCYT

VCYT Price/Volume Stats

Current price $20.58 52-week high $32.40
Prev. close $21.91 52-week low $14.85
Day low $20.55 Volume 732,104
Day high $22.03 Avg. volume 734,127
50-day MA $24.35 Dividend yield N/A
200-day MA $23.00 Market Cap 1.48B

Veracyte, Inc. (VCYT) Company Bio


Veracyte Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company was founded in 2006 and is based in San Francisco, California.


VCYT Latest News Stream


Event/Time News Detail
Loading, please wait...

VCYT Latest Social Stream


Loading social stream, please wait...

View Full VCYT Social Stream

Latest VCYT News From Around the Web

Below are the latest news stories about VERACYTE INC that investors may wish to consider to help them evaluate VCYT as an investment opportunity.

Estimating The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Veracyte fair value estimate is US$20.37 Current share price...

Yahoo | March 23, 2023

7 Biotech Stocks That Could Be the Next Big Thing

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

Josh Enomoto on InvestorPlace | March 15, 2023

Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners

SOUTH SAN FRANCISCO, Calif., March 15, 2023--Veracyte Announces Abstracts to Be Presented at AACR Annual Meeting Highlighting Company's Multi-Omics Capabilities & Tools for Biopharma Partners

Yahoo | March 15, 2023

Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank

SOUTH SAN FRANCISCO, Calif., March 11, 2023--Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB).

Yahoo | March 11, 2023

Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?

Rising interest rates and fears of a recession have caused a great deal of uncertainty over the past 12 months. Let's dig into Veracyte's fundamentals and valuation to get an answer to that question. Diagnostic tests are critical to helping doctors and hospitals run the healthcare system as smoothly as possible.

Yahoo | March 10, 2023

Read More 'VCYT' Stories Here

VCYT Price Returns

1-mo -13.46%
3-mo -12.13%
6-mo 23.68%
1-year -26.05%
3-year -11.14%
5-year 270.14%
YTD -13.27%
2022 -42.40%
2021 -15.82%
2020 75.29%
2019 121.94%
2018 92.65%

Continue Researching VCYT

Want to see what other sources are saying about Veracyte Inc's financials and stock price? Try the links below:

Veracyte Inc (VCYT) Stock Price | Nasdaq
Veracyte Inc (VCYT) Stock Quote, History and News - Yahoo Finance
Veracyte Inc (VCYT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.9245 seconds.